Cancer medicines are among the fastest-growing areas of healthcare expenditure, making robust evidence essential for informing policy, funding, and clinical decision-making. While advances in cancer therapeutics have improved outcomes for many patients, they have also created new challenges around access, affordability, value, and equity. In this context, real-world data play a critical role in ensuring that medicines policy is informed by timely real-world evidence. This presentation will explore how linked real-world medicines data can be used to evaluate patterns of medicine use, treatment outcomes, safety, and equity of access. Drawing on examples from cancer pharmacoepidemiology research, it will demonstrate how population-level evidence can inform reimbursement decisions, guide policy development, identify unmet need, and support more effective and sustainable cancer care. The presentation will highlight the growing importance of real-world evidence in understanding the impact of cancer medicines beyond clinical trials and in addressing variation in outcomes across populations. Attendees will gain insights into how cancer data can be translated into actionable evidence that supports better medicines policy, more equitable access to treatment, and improved outcomes for people affected by cancer.